What is Lifesci Capital’s Estimate for ABVX FY2025 Earnings?

ABIVAX Société Anonyme (NASDAQ:ABVX) – Analysts at Lifesci Capital issued their FY2025 earnings estimates for ABIVAX Société Anonyme in a report issued on Tuesday, March 25th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings per share of ($3.14) for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share.

Several other brokerages have also weighed in on ABVX. JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. Finally, Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $38.00.

ABIVAX Société Anonyme Trading Down 0.4 %

ABVX opened at $7.34 on Wednesday. The company’s 50-day moving average price is $6.77 and its two-hundred day moving average price is $8.43. ABIVAX Société Anonyme has a twelve month low of $5.50 and a twelve month high of $16.63.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Kennedy Capital Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company’s stock worth $1,650,000 after buying an additional 1,656 shares in the last quarter. Bank of America Corp DE increased its holdings in ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares during the period. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter worth approximately $29,000. R Squared Ltd bought a new position in ABIVAX Société Anonyme in the 4th quarter valued at $36,000. Finally, BNP Paribas Financial Markets boosted its holdings in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. Institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.